Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT327 with or without temozolomide in recurrent glioblastoma
CTR20255042Phase 2Active
- Sponsor
- BioNTech
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in glioblastoma (GBM), sponsored by BioNTech. Started Dec 2025; status: active.
02
Drugs
pumitamig
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20255042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255042.